Identifying and Treating Depression in Hemodialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
DepressionHemodialysis-Induced Symptom
Interventions
DRUG

Fluoxetine

Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.

Trial Locations (1)

44109

MetroHealth Medical Center, Cleveland

All Listed Sponsors
lead

MetroHealth Medical Center

OTHER

NCT03390933 - Identifying and Treating Depression in Hemodialysis Patients | Biotech Hunter | Biotech Hunter